Literature DB >> 8656266

Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology.

.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8656266     DOI： 10.1200/JCO.1996.14.6.1957

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  25 in total

1.  Impact of ASCO guidelines for the use of hematopoietic colony stimulating factors (CSFs): survey results of fifteen Paris university hospitals.

Authors:  I Debrix; I Madelaine; N Grenet; D Roux; C Bardin; F Le Mercier; J E Fontan; O Connor; A Pointereau; P Tilleul
Journal:  Pharm World Sci       Date:  1999-12

Review 2.  Methodological hurdles in conducting pharmacoeconomic analyses.

Authors:  J D Rizzo; N R Powe
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

Review 3.  Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J C de Graaf; J L Coenen; J R Brouwers
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies.

Authors:  A K Sood; J I Sorosky; R C Squatrito; J S Skilling; B Anderson; R E Buller
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 5.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

6.  Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness.

Authors:  Takeshi Hara; Hisashi Tsurumi; Senji Kasahara; Nobuhiro Kanemura; Takeshi Yoshikawa; Naoe Goto; Yasushi Kojima; Toshiki Yamada; Michio Sawada; Takeshi Takahashi; Masami Oyama; Eiichi Tomita; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

7.  Different effect of granulocyte colony-stimulating factor or bacterial infection on bone-marrow cells of cyclophosphamide-treated or irradiated mice.

Authors:  A M Buisman; T L Van Zwet; J A Langermans; M F Geertsma; P J Leenen; R van Furth
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

Review 8.  The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.

Authors:  Der-Cherng Liang
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).

Authors:  Vicki A Morrison; Edie A Weller; Thomas M Habermann; Shuli Li; Richard I Fisher; Bruce D Cheson; Bruce A Peterson
Journal:  Leuk Lymphoma       Date:  2016-12-14

10.  Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.

Authors:  Lori J Goldstein; Anne O'Neill; Joseph A Sparano; Edith A Perez; Lawrence N Shulman; Silvana Martino; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2008-08-04       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.